创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: PDC High-Throughput In Vitro Drug Discovery

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-11 15:30
  • Views:

(Summary description)InnoModels Biotechnology is committed to driving technological innovation in the life sciences, and its PDC (Phenotypic Drug Discovery) high-throughput in vitro efficacy technology plays an important role in drug discovery, not only providing highly reduced biological models, but also accelerating the process of drug screening and evaluation, enabling researchers to find promising drug candidates faster and more accurately. PDC technology not only provides highly reductive biological models, but also accelerates the process of drug screening and evaluation, enabling researchers to find potential drug candidates more quickly and accurately

InnoModels Biotechnology: PDC High-Throughput In Vitro Drug Discovery

(Summary description)InnoModels Biotechnology is committed to driving technological innovation in the life sciences, and its PDC (Phenotypic Drug Discovery) high-throughput in vitro efficacy technology plays an important role in drug discovery, not only providing highly reduced biological models, but also accelerating the process of drug screening and evaluation, enabling researchers to find promising drug candidates faster and more accurately. PDC technology not only provides highly reductive biological models, but also accelerates the process of drug screening and evaluation, enabling researchers to find potential drug candidates more quickly and accurately

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-11 15:30
  • Views:
Information

InnoModels Biotechnology is committed to driving technological innovation in the life sciences, and its PDC (Phenotypic Drug Discovery) high-throughput in vitro efficacy technology plays an important role in drug discovery, not only providing highly reduced biological models, but also accelerating the process of drug screening and evaluation, enabling researchers to find promising drug candidates faster and more accurately. PDC technology not only provides highly reductive biological models, but also accelerates the process of drug screening and evaluation, enabling researchers to find potential drug candidates more quickly and accurately.
Definition of PDC High-Throughput In Vitro Efficacy Studies
PDC is a cellular phenotype-based drug discovery method. Compared to traditional target-driven drug discovery, PDC technology focuses on providing more comprehensive information for drug discovery through the comprehensive observation and assessment of drug effects at the cellular level.
InnoModels Bio's PDC high-throughput in vitro drug discovery technology
InnoModels Biotechnology has made remarkable achievements in PDC high-throughput in vitro drug efficacy study technology, and its technology has unique advantages in the following aspects:
1. Multi-parameter determination:
PDC technology allows researchers to simultaneously assess multiple cell phenotypic parameters, such as cell proliferation, cell cycle, apoptosis, etc., providing a more comprehensive understanding of drug effects.
2. Multi-cell type support:
The technology supports the application of multiple cell types, including tumour cells, primary cells, etc., which is suitable for drug research in different disease areas.
3. High-throughput screening:
The PDC technology of InnoModels Biotechnology can screen a large number of drugs in a relatively short time, which improves the research efficiency and provides strong support for efficient drug discovery.
4. Complex disease modelling:
Combined with multi-parameter cellular phenotyping, PDC technology makes it possible to establish more complex disease models, which helps to study the effects of drugs in complex disease environments.

 


Application Areas
InnoModels Bio's PDC technology has been widely used in the following areas:
Anti-cancer drug development:
Accelerating the discovery and development process of anti-cancer drugs through multi-parameter evaluation of tumour cells.
Neurological disease research:
Helps researchers better understand drug effects in the nervous system by modelling complex neurological diseases.
Infectious Disease Drug Development:
Provides an efficient and comprehensive in vitro research platform for infectious disease research, accelerating the discovery of antiviral drugs.
Conclusion
InnoModels Bio's PDC high-throughput in vitro drug efficacy research technology is not only a model of technological innovation, but also plays an important role in the field of drug discovery and development. Through comprehensive cellular phenotype assessment, this technology provides a more comprehensive and reliable research platform for drug discovery and opens new doors for drug innovation for researchers.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司